



**MSN Laboratories Private Limited
R&D Center. Formulation Division.**

SAFETY DATA SHEET

Product Name	Chlorpromazine Hydrochloride Tablets USP 25 mg, 50 mg, 100 mg and 200 mg	Page No 1 of 4
---------------------	---	-----------------------

1. Identification of the substance/mixture and the company/undertaking

Product Name: Chlorpromazine Hydrochloride Tablets USP 25 mg, 50 mg, 100 mg and 200 mg

Chemical Family: Mixture

Intended use: Antipsychotic

Details of the manufacturer:

MSN Laboratories Private Limited.

Formulation Division, Unit - II,

Sy No 1277 & 1319 to 1324

Nandigama Village & Mandal

Ranga Reddy Dist

Telangana State, India.

PIN 509228

Phone: +91 40 3044 9200

2. Hazards Identification

Handling should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients Moderate to severe irritant to the skin and eyes.

3. Composition/Information on Ingredients

C.A.S. No : 69-09-0

Molecular Formula : $C_{17}H_{19}ClN_2S \cdot HCl$

Molecular Weight : 355.33 g/mol

Chemical Name : 2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine monohydrochloride

4. First Aid Measures

If Inhaled:

Remove to fresh air. If breathing is irregular or stopped, administer artificial respiration. Call a physician immediately

In case of skin contact:

Wash off immediately with plenty of water for at least 15 minutes. Takeoff all contaminated clothing immediately. Get medical attention if irritation develops and persists

In case of eye contact:

In case of eye contact, remove contact lens and rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Obtain medical attention.



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Chlorpromazine Hydrochloride Tablets USP 25 mg, 50 mg, 100 mg and 200 mg	Page No 2 of 4
---------------------	---	-----------------------

If swallowed:

If conscious, give the victim plenty of water to drink. Never give anything by mouth to an unconscious person. Call a physician immediately.

5. Fire Fighting Measures

Suitable extinguishing media: Carbon dioxide, dry chemical powder. Water spray

Special protective equipment: Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

6. Accidental Release Measures

Personal precautions: Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation. Evacuate personnel to safe areas.

Environmental precautions: Prevent further leakage or spillage. Do not let product enter into drains. Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.

7. Handling and Storage

Precautions for safe handling: Use all suitable protective clothing and equipment like goggles, hand gloves etc... Do not ingest. Avoid contact with skin and eyes. Handle the material under nitrogen atmosphere or in de-humidified condition.

Conditions for safe storage:

Preserve in tight light-resistant containers.

Protect from moisture.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]

8. Exposure Controls/Personal Protection

Personal protective equipment: Glasses, Gloves, Respirator, Particulate etc

Respiratory protection: Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection: The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Handle with gloves.

Eye protection: Wear protective chemical safety goggles.

FDQA CONTROLLED COPY



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Chlorpromazine Hydrochloride Tablets USP 25 mg, 50 mg, 100 mg and 200 mg	Page No 3 of 4
--------------	--	----------------

Skin and body protection: Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Hygiene measures: Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

9. Physical and Chemical Properties

Appearance :

25 mg : Light yellow to yellow colored, round shaped, biconvex, sugar coated tablets imprinted "C2" with black ink on one side and plain on other side, free from physical defects

50 mg : Light yellow to yellow colored, round shaped, biconvex, sugar coated tablets imprinted "C3" with black ink on one side and plain on other side, free from physical defects

100 mg : Light yellow to yellow colored, round shaped, biconvex, sugar coated tablets imprinted "C4" with black ink on one side and plain on other side, free from physical defects

200 mg : Light yellow to yellow colored, round shaped, biconvex, sugar coated tablets imprinted "C5" with black ink on one side and plain on other side, free from physical defects

10. Stability and Reactivity

Chemical stability: Stable under recommended storage conditions

Conditions to avoid: Light, Heat, flame, sparks.

Materials to avoid: Keep away from strong oxidizers.

Hazardous decomposition products: Formation of toxic gases is possible during heating or in case of fire

11. Toxicological Information

Acute toxicity: LD₅₀ (Oral, Rat): 225 mg/kg

Skin corrosion/irritation: Irritant to skin and mucous membranes.

Serious eye damage/eye irritation: Irritating effect

Respiratory or skin sensitization: No sensitizing effects known.

Mutagenicity: No data available.

Carcinogenicity: Chlorpromazine HCl is not carcinogenic.

Reproductive toxicology & Teratology: No data available.

Specific target organ toxicity-repeated exposure: Causes damage to organs (nervous system) through prolonged or repeated exposure.

Aspiration hazard: No data available

Potential health effects:

PDQA CONTROLLED COPY



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Chlorpromazine Hydrochloride Tablets USP 25 mg, 50 mg, 100 mg and 200 mg	Page No 4 of 4
--------------	--	----------------

Ingestion: May be toxic if swallowed.

Skin: May be toxic if absorbed through skin. May cause skin irritation.

Eyes: May cause eye irritation.

Additional Information

RTECS: Not available

12. Ecological Information

Not data available

13. Disposal Considerations

Product: Observe all federal, state, and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging: Dispose of as unused product.

14. Transport Information

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. Regulatory Information

This safety data sheet complies with the requirements of Regulation (EC) No. 1272/2008/EC.

16. Other Information

Text of H-code(s) and R-phrases(s) and S-Phrase(s) mentioned in Section 3

H-Codes :

H301 : Toxic if swallowed.

H311 : Toxic in contact with skin.

H331 : Toxic if inhaled.

R-Phrase(s) :

R23/24/25: Toxic by inhalation, toxic in contact with skin and toxic if swallowed

Notice: The information and recommendations in this safety data sheet are to the best of our knowledge, accurate at the date of issue. Nothing herein shall be deemed to create any warranty expressed or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material for any particular purpose.

FDQA CONTROLLED COPY

Effective Date: 02/12/2022